{"id":962091,"date":"2026-05-13T08:04:31","date_gmt":"2026-05-13T12:04:31","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/"},"modified":"2026-05-13T08:04:31","modified_gmt":"2026-05-13T12:04:31","slug":"charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/","title":{"rendered":"Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions<\/b><\/p>\n<p class=\"bwalignc\"><i>Partnership showcases a forward-<\/i><i>looking collaboration model that highlights advanced testing expertise<\/i><\/p>\n<p>WILMINGTON, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nCharles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River\u2019s expertise in biologics and cell therapy GMP testing to support MEDIPOST\u2019s global cell therapy pipeline, starting in the Asia-Pacific (APAC) and North America (NA) regions, with possible expansion into Middle East and Europe.<\/p>\n<p id=\"news-body-cta\">This press release features multimedia. View the full release here: <a href=\"https:\/\/www.businesswire.com\/news\/home\/20260513434668\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260513434668\/en\/<\/a><\/p>\n<div id=\"bwbodyimg\" style=\"width: 480px;float:left;padding-left:0px;padding-right:20px;padding-top:0px;padding-bottom:0px\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260513434668\/en\/2798878\/4\/Charles_River_and_MEDIPOST_Signed_MoU.jpg\" alt=\"Charles River and MEDIPOST signed non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing and commercial and marketing efforts.\" \/><\/p>\n<p style=\"font-size:85%\">Charles River and MEDIPOST signed non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing and commercial and marketing efforts.<\/p>\n<\/div>\n<p>\n\u201cWe are excited to deepen our partnership with MEDIPOST and collaborate with a top global cell therapy developer, assisting at both clinical and commercialization phases,\u201d said Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River. \u201cBy collaborating with industry leaders, we aim to expand GMP testing capabilities and help ensure that safe, compliant products reach patients more efficiently.\u201d<\/p>\n<p>\nCharles River will provide specialized expertise in biologics quality control, viral testing, release testing, and other GMP-compliant services, supporting MEDIPOST from development through commercialization. Through this non-exclusive MOU, Charles River continues to advance efficient, high-quality, and compliant development pathways for advanced biologics, particularly within the APAC region. The collaboration reflects a shared commitment to accelerating access to safe, effective cell therapies across global markets.<\/p>\n<p>\n\u201cWe are pleased to announce this collaborative partnership with Charles River Laboratories, a true global-standard player and services provider in the field of biologics research and development,\u201d said Antonio (Tony) Lee, Global President and Board Director at MEDIPOST.<\/p>\n<p>\n\u201cWith over 14 years of commercial-stage allogeneic cell therapy product manufacturing and release experience, treating more than 36,000 patients within South Korea, MEDIPOST is now expanding into global regions starting with APAC and North America. Our partnership with Charles River will help us pave solid paths to efficient and compliant commercial pathways in multiple regulatory jurisdictions across the globe.\u201d<\/p>\n<p><b>Biologics Testing Solutions<\/b><\/p>\n<p>\nCharles River Laboratories provides <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.criver.com%2Fproducts-services%2Fbiologics-testing-solutions&amp;esheet=54531394&amp;newsitemid=20260513434668&amp;lan=en-US&amp;anchor=comprehensive+biologics+testing&amp;index=1&amp;md5=e9086b8a175a3e932cd9d2a46397279e\">comprehensive biologics testing<\/a>, scientific expertise, and regulatory guidance to help keep development programs on track. As a global partner with GMP-compliant facilities across North America and Europe, the company supports biologics and advanced therapy programs across multiple modalities through an integrated, end-to-end approach. By reducing reliance on fragmented vendor networks, Charles River helps minimize operational risk, strengthen regulatory readiness, and accelerate progress toward clinical and commercial approval.<\/p>\n<p><b>About MEDIPOST<\/b><\/p>\n<p>\nMEDIPOST Co., Ltd. is a commercial-stage biotechnology company developing allogeneic, umbilical cord blood-derived mesenchymal stem\/stromal cell (MSC) therapies for degenerative diseases including knee Osteoarthritis. The company has a regulatory-approved allogeneic stem cell product \u2013 CARTISTEM<sup>\u00ae<\/sup> on the market in South Korea with Phase 3 pivotal studies ongoing in Japan and the U.S., and an additional pipeline of regenerative medicine products built on its proprietary stem cell technology platform with a focus on scalable, off-the-shelf therapeutic approaches. Learn more at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.medi-post.com&amp;esheet=54531394&amp;newsitemid=20260513434668&amp;lan=en-US&amp;anchor=www.medi-post.com&amp;index=2&amp;md5=a5ed2e72c06177ceb914668d12d2422d\">www.medi-post.com<\/a>.<\/p>\n<p><b>About Charles River<\/b><\/p>\n<p>\nCharles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.criver.com&amp;esheet=54531394&amp;newsitemid=20260513434668&amp;lan=en-US&amp;anchor=www.criver.com&amp;index=3&amp;md5=2c7301f2153ab424d15da4494303e261\">www.criver.com<\/a>.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260513434668r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260513434668\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260513434668\/en\/<\/a><\/span><\/p>\n<p><b>Charles River Investor Contact:<br \/>\n<\/b><br \/>Todd Spencer<br \/>\n<br \/>Corporate Vice President,<br \/>\n<br \/>Investor Relations<br \/>\n<br \/>781.222.6455<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:todd.spencer@crl.com\">todd.spencer@crl.com<br \/>\n<\/a><\/p>\n<p><b>Charles River Media Contact:<br \/>\n<\/b><br \/>Amy Cianciaruso<br \/>\n<br \/>Corporate Senior Vice President,<br \/>\n<br \/>Chief Communications Officer<br \/>\n<br \/>781.222.6168<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:amy.cianciaruso@crl.com\">amy.cianciaruso@crl.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> Massachusetts South Korea United States North America Asia Pacific<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Medical Devices General Health Research Science Pharmaceutical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Photo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260513434668\/en\/2798878\/3\/Charles_River_and_MEDIPOST_Signed_MoU.jpg\" alt=\"Photo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\">Charles River and MEDIPOST signed non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing and commercial and marketing efforts.<\/font><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260513434668\/en\/836653\/3\/charles_river_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions Partnership showcases a forward-looking collaboration model that highlights advanced testing expertise WILMINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211; Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River\u2019s expertise in biologics and cell therapy GMP testing to support MEDIPOST\u2019s global cell therapy pipeline, starting in the Asia-Pacific (APAC) and North America (NA) regions, with possible expansion into Middle East and Europe. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260513434668\/en\/ Charles River and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-962091","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions Partnership showcases a forward-looking collaboration model that highlights advanced testing expertise WILMINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211; Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River\u2019s expertise in biologics and cell therapy GMP testing to support MEDIPOST\u2019s global cell therapy pipeline, starting in the Asia-Pacific (APAC) and North America (NA) regions, with possible expansion into Middle East and Europe. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260513434668\/en\/ Charles River and &hellip; Continue reading &quot;Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-13T12:04:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260513434668\/en\/2798878\/4\/Charles_River_and_MEDIPOST_Signed_MoU.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions\",\"datePublished\":\"2026-05-13T12:04:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\\\/\"},\"wordCount\":706,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260513434668\\\/en\\\/2798878\\\/4\\\/Charles_River_and_MEDIPOST_Signed_MoU.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\\\/\",\"name\":\"Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260513434668\\\/en\\\/2798878\\\/4\\\/Charles_River_and_MEDIPOST_Signed_MoU.jpg\",\"datePublished\":\"2026-05-13T12:04:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260513434668\\\/en\\\/2798878\\\/4\\\/Charles_River_and_MEDIPOST_Signed_MoU.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260513434668\\\/en\\\/2798878\\\/4\\\/Charles_River_and_MEDIPOST_Signed_MoU.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/","og_locale":"en_US","og_type":"article","og_title":"Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions - Market Newsdesk","og_description":"Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions Partnership showcases a forward-looking collaboration model that highlights advanced testing expertise WILMINGTON, Mass.&#8211;(BUSINESS WIRE)&#8211; Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River\u2019s expertise in biologics and cell therapy GMP testing to support MEDIPOST\u2019s global cell therapy pipeline, starting in the Asia-Pacific (APAC) and North America (NA) regions, with possible expansion into Middle East and Europe. This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260513434668\/en\/ Charles River and &hellip; Continue reading \"Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-13T12:04:31+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260513434668\/en\/2798878\/4\/Charles_River_and_MEDIPOST_Signed_MoU.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions","datePublished":"2026-05-13T12:04:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/"},"wordCount":706,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260513434668\/en\/2798878\/4\/Charles_River_and_MEDIPOST_Signed_MoU.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/","name":"Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260513434668\/en\/2798878\/4\/Charles_River_and_MEDIPOST_Signed_MoU.jpg","datePublished":"2026-05-13T12:04:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260513434668\/en\/2798878\/4\/Charles_River_and_MEDIPOST_Signed_MoU.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260513434668\/en\/2798878\/4\/Charles_River_and_MEDIPOST_Signed_MoU.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/charles-river-laboratories-and-medipost-sign-non-exclusive-mou-to-advance-gmp-testing-solutions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962091","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=962091"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/962091\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=962091"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=962091"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=962091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}